Introduction
============

Diabetes has become one of the most important diseases worldwide, with the proportion of the adult population with diabetes expected to increase to 69% by 2030 ([@b1-etm-0-0-4113]). Diabetes mellitus is a metabolic disease characterized by prolonged hyperglycemia, which can lead to the development of microvascular and macrovascular disease ([@b2-etm-0-0-4113]). Hyperglycemia at the macrovascular level causes coronary artery and cerebrovascular diseases, and at the microvascular level injury mainly affects the eye, kidney and liver. Diabetic hepatic damage is the most common cause of end-stage liver disease, namely cirrhosis, and contributes to disability and the high mortality rate in patients with diabetes. The pathogenesis of diabetic hepatic damage is multifactorial, with long-term hyperglycemia playing a crucial role ([@b3-etm-0-0-4113],[@b4-etm-0-0-4113]). During diabetes mellitus, the continuous hyperglycemic conditions are associated with oxidative stress and the mitochondrial production of free radicals, which lead to hepatic dysfunction ([@b5-etm-0-0-4113]). One of the main factors in the initiation of the pathological response to oxidative stress is the generation of reactive oxygen species (ROS). According to a previous study, increased nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-4 (Nox-4)/p47^phox^ is associated with elevated ROS generation, implying the potential importance of Nox-4-based NADPH oxidase in the oxidative damage associated with diabetic hepatism ([@b6-etm-0-0-4113]). Moreover, increased ROS production is associated with inflammation and indirectly damages cells by activating a variety of stress-sensitive intracellular signaling pathways. Also, ROS-mediated activation of nuclear factor (NF)-κB and the c-Jun subunit of activator protein-1 (AP-1), two redox-sensitive transcription factors, are evolutionarily conserved and associated with a wide variety of pro-inflammatory mediators, including cytokines, chemokines, and inducible effector enzymes such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) ([@b7-etm-0-0-4113]).

*Oenanthe javanica* (water dropwort), which is cultivated in Australia and East Asian countries, such as Korea, China and Japan is a perennial herb. *O. javanica*, which contains high levels of vitamins and minerals, is consumed as a vegetable, and has also been used as a medicinal agent. It has a long history of use for the treatment of inflammatory conditions, including hepatitis ([@b8-etm-0-0-4113],[@b9-etm-0-0-4113]). Hyperoside, persicarin and isorhamnetin are the three major substances with pharmacological activities that have been identified in *O. javanica*. These substances have been shown to possess hepatoprotective, antithrombotic, antiarrhythmic, antidiabetic, antihepatitis B virus, neuroprotective and anticancer activities ([@b9-etm-0-0-4113]--[@b16-etm-0-0-4113]).

Persicarin has been reported to exhibit neuroprotective and antioxidant activities against glutamate-induced neurotoxicity in primary cultured rat cortical cells ([@b14-etm-0-0-4113]). In addition, persicarin has exhibited an anti-inflammatory effect against high mobility group box 1-induced inflammatory responses in human endothelial cells and in a cecal ligation and puncture model of septicemia in mice ([@b17-etm-0-0-4113]). However, to the best of our knowledge, no studies have yet been performed on the antidiabetic activity of persicarin.

Therefore, in the present study, the effects of persicarin on the oxidative stress-related factors involved in the development of diabetic hepatic damage were investigated using streptozotocin (STZ)-induced type 1 diabetic mice.

Materials and methods
=====================

### Materials

Ethylenediaminetetraacetic acid (EDTA) was purchased from Generay Biotech Co. Ltd. (Shanghai, China). 2′,7′-Dichlorofluorescein diacetate (DCFH-DA) was obtained from Molecular Probes (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The protease inhibitor mixture was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Dihydrorhodamine 123 (DHR123) and diethylene triamine penta-acetic acid (DTPA) were purchased from Sigma-Aldrich (Merck Millipore, Darmstadt, Germany). Isoflurane (1%) was purchased from Piramal Critical Care, Inc., (Bethlehem, PA, USA). The Bio-Rad protein assay kit and pure nitrocellulose membrane were supplied by Bio-Rad Laboratories (Seoul, Korea). Phenylmethylsulfonyl fluoride (PMSF) and sodium dodecyl sulfate (SDS) were acquired from (Amresco, LLC, Solon, OH, USA). PBS-Tween (P2006) was obtained from Biosesang, Inc., (Gyeonggi-do, Korea). Rabbit polyclonal antibodies against Nox-4 (cat. no. sc-30141), p47^phox^ (cat. no. sc-14015) and NF-κBp65 (cat. no. sc-372), and mouse monoclonal antibodies against COX-2 (cat. no. sc-19999), iNOS (cat. no. sc-372), histone (cat. no. sc-8030) and β-actin (cat. no. sc-4778), and goat polyclonal antibodies against transforming growth factor (TGF)-β (cat. no. sc-146) and tumor necrosis factor (TNF)-α (cat. no. sc-1351) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Rabbit polyclonal anti-AP-1 (cat. no. 2315S) was obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Goat anti-rabbit (cat. no. sc-2774) and goat anti-mouse (cat. no. sc-2005) immunoglobulin G (IgG) horseradish peroxidase (HRP)-conjugated secondary antibodies were acquired from Santa Cruz Biotechnology, Inc. ECL Western Blotting Detection Reagents were supplied by GE Healthcare (Piscataway, NJ, USA).

### Preparation of persicarin extracts

The aerial parts of *O. javanica* were collected from agricultural farms in Pyeongyang-ri, Cheongdo-gun, Gyoungsanbuk-do, South Korea in April 2011, and identified by Professor Tae Hoon Kim (Daegu University, Daegu, South Korea). Freshly milled *O. javanica* plant material (1.4 kg) was extracted with 70% ethanol (EtOH; 10 liters, thrice) at room temperature. The solvent was then evaporated under vacuum, and the combined crude EtOH extract (81.5 g) was suspended in 20% methanol (MeOH; 3 liters), and partitioned sequentially against *n*-hexane (3 liters, thrice), ethyl acetate (EtOAc; 3 liters, thrice), and *n*-butanol (BuOH; 3 liters, thrice) to yield dried *n*-hexane-(5.5 g), EtOAc-(1.8 g), *n*-BuOH (10.6 g) and H~2~O-soluble (53.6 g) residues. A portion (1.7 g) of the EtOAc extract was chromatographed using a column containing Toyopearl HW-40 \[coarse grade; 3.0 cm internal diameter (i.d.)x48 cm\] using water containing increasing amounts of MeOH in a stepwise manner. The 100% H~2~O eluate obtained was subjected to column chromatography using YMC GEL ODS AQ 120-50S (1.6 cm i.d.x37 cm) using aqueous MeOH, to yield pure compound 1 (75.9 mg; retention time, 10.1 min). HPLC analysis was carried out using a YMC-Pack ODS A-302 column (4.6 mm i.d.x150 mm; YMC Co., Kyoto, Japan) with a linear gradient of 10% (v/v) acetonitrile (MeCN) in 0.1% formic acid/H~2~O (detection, UV 280 nm; flow rate, 1.0 ml/min; 40°C), which was increased to 90% MeCN over 30 min and then to 100% MeCN over 5 min. Compound 1 was identified and characterized as persicarin by ^1^H and ^13^C NMR and by comparing peaks with literature values ([@b18-etm-0-0-4113]). The ^1^H NMR results were as follows: (600 MHz, DMSO-d~6~) δ 8.06 (1H, d, J= 2.2 Hz, H-2′), 7.61 (1H, d, J=8.8, 2.2 Hz, H-6′), 6.92 (1H, d, J=8.8 Hz, H-5′), 6.43 (1H, d, J=2.2 Hz, H-8), 6.22 (1H, d, J=2.2 Hz, H-6), 3.83 (3H, s, MeO-3′). The ^13^C NMR results were as follows: (150 MHz, DMSO-d~6~) δ 177.1 (C-4), 166.5 (C-7), 161.1 (C-5), 156.2 (C-2), 155.5 (C-9), 149.6 (C-3′), 147.1 (C-4′), 131.8 (C-5′), 121.2 (C-6′), 121.1 (C-1′), 115.2 (C-2′), 103.1 (C-10), 99.7 (C-6), 93.6 (C-8), 55.6 (MeO).

### Experimental animals and treatment

Animal experiments were performed according to the Guidelines for Animal Experimentation and approved by Daegu Haany University (approval no. DHU2015-011). A total of 24, 5-week-old male ICR mice (23--28 g) were purchased from Orient Bio Inc. (Gyeonggi, Korea). Mice were maintained under a 12-h light/dark cycle, and housed at a controlled temperature (22±2°C) and humidity (55±5%) with free access to food and water. After several days of adaptation, the mice were randomly separated into normal control (n=6) and diabetic groups. Mice in the diabetic group were injected intraperitoneally with STZ (Sigma-Aldrich; 120 mg/kg body weight) in 10 mM citrate buffer (pH 4.5). After 7 days of STZ injection, the glucose levels of blood taken from the tail vein were measured, and then the STZ-induced diabetic mice were divided into three groups (each n=6). Treatment with persicarin was initiated after confirming the induction of hyperglycemia in the diabetic mice by weight (33.8±0.5 g) and serum glucose level (288.3±6.5 mg/dl). Mice in the diabetic control group (Veh group) were given water orally, while those in the other two diabetic groups were orally treated with persicarin extracts daily for 10 days at a low or high dose (2.5 and 5 mg/kg body weight, respectively). The diabetic groups were compared with the normal (non-diabetic) control group. Body weight, food intake and water intake were determined every day during the experimental period. After administration for 10 days, mice were anesthetized with 1% isoflurane and blood samples were collected from the abdominal aorta of anesthetized mice. Serum was separated immediately by centrifugation. Subsequently, each mouse was perfused with ice-cold physiological saline, and then the liver was harvested, snap-frozen in liquid nitrogen and stored at −80°C until analyses were performed.

### Analysis of serum and hepatic functional parameters

The serum glucose level was measured using a commercial kit (Glucose Test, cat. no. AM201; Asan Pharm. Co., Ltd., Hwaseong, South Korea). Hepatic functional parameters \[alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\] were measured using a Transaminase CII-Test kit (cat. no. 431-30901; Wako Pure Chemical Industries, Ltd.).

### Analysis of hepatic glucose content

The hepatic glucose level was determined using the method of Momose *et al* ([@b19-etm-0-0-4113]), with minor modifications. Hepatic tissue was homogenized with ice-cold 0.9% NaCl buffer, and then the homogenate was deproteinized with 0.15 M Ba(OH)~2~ and 5% ZnSO~4~. The supernatant was obtained by centrifugation at 1,670 × g for 15 min, and then the glucose level was determined using the aforementioned glucose test kit.

### Measurement of hepatic ROS generation and thiobarbituric acid reactive substance (TBARS) levels

ROS generation was measured using the method of Ali *et al* ([@b20-etm-0-0-4113]). Hepatic tissue was homogenized on ice with 1 mM EDTA-50 mM sodium phosphate buffer (pH 7.4), and then 25 mM DCFH-DA was added to the homogenates. After incubation for 30 min, the changes in fluorescence values were determined at an excitation wavelength of 486 nm and emission wavelength of 530 nm. The TBA-reactive substance content was determined using the method of Mihara and Uchiyama ([@b21-etm-0-0-4113]).

### Measurement of peroxynitrite (ONOO^−^) generation in the liver

ONOO^−^ was measured by the method of Kooy *et al* ([@b22-etm-0-0-4113]). Each sample was mixed with rhodamine buffer (pH 7.4), 5 mM DTPA and 5 mM DHR123. After incubation for 5 min at 37°C, the fluorescence intensity of the oxidized DHR123 was measured with a microplate fluorescence reader at excitation and emission wavelengths of 485 and 530 nm, respectively.

### Preparation of nuclear and post-nuclear fractions

Nuclear protein extraction was performed using the method reported by Komatsu ([@b23-etm-0-0-4113]). Briefly, liver tissue was homogenized with ice-cold lysis buffer containing 5 mM Tris-HCl (pH 7.5), 2 mM MgCl~2~, 15 mM CaCl~2~ and 1.5 M sucrose, followed by the addition of a 0.1 M dithiothreitol (DTT) and a protease inhibitor mixture. After centrifugation (10,500 × g for 20 min at 4°C), the pellet was suspended with an extraction buffer containing 20 mM 2-\[4-(2-hydroxyethyl)-1-piperazyl\] ethanesulfonic acid (pH 7.9), 1.5 mM MgCl~2~, 0.42 M NaCl, 0.2 mM EDTA and 25% (v/v) glycerol, followed by the addition of a 0.1 M DTT and protease inhibitor mixture. The mixture was placed on ice for 30 min. The nuclear fraction was prepared by centrifugation at 20,500 × g for 5 min at 4°C.

The post-nuclear fraction was extracted from the kidneys of each mouse. Briefly, liver tissue was homogenized with ice-cold lysis buffer (pH 7.4) containing 137 mM NaCl, 20 mM Tris-HCl, 1% Tween 20, 10% glycerol, 1 mM PMSF, and a protease inhibitor mixture. The homogenate was then centrifuged at 2,000 × g for 10 min at 4°C, and the protein concentration in each fraction was determined using a Bio-Rad protein assay kit.

### Western blot analyses

To determine the expression of NF-κBp65, AP-1 and histone, 10 µg protein from each nuclear fraction was separated by 8% SDS-PAGE. For Nox-4/p47^phox^, COX-2, iNOS, TGF-β and β-actin , 10 µg protein of each post-nuclear fraction was separated by 8--15% SDS-PAGE. The separated proteins were transferred to a nitrocellulose membrane, blocked with a 5% (w/v) skimmed milk solution for 1 h, and incubated separately with the primary antibodies (NF-κBp65, AP-1, histone, Nox-4/p47^phox^, COX-2, iNOS, TGF-β and β-actin) overnight at 4°C at a dilution of 1:1,000. Following washing with PBS-Tween, the blots were incubated with the anti-rabbit or anti-mouse IgG HRP-conjugated secondary antibody for 1 h at room temperature at a dilution of 1:3,000. Each antigen-antibody complex was visualized using ECL Western Blotting Detection Reagents and detected using SENSI-Q2000 (Lugen Sci. Co., Ltd., Gyeonggi, South Korea). The band densities were determined using ATTO Densitograph software (CS Analyzer 2.0; ATTO Corporation, Tokyo, Japan), and quantified as a ratio to β-actin. The protein levels of the groups are expressed relative to those of the normal mice (represented as 1).

### Histological examination

The excised liver samples were immediately fixed in 10% neutral-buffered formalin and, after embedding in paraffin, they were cut into 5-µm sections. After staining with hematoxylin and eosin (H&E), the sections were examined with a light microscope.

### Statistical analysis

Data are expressed as the mean ± standard error of the mean. Statistical comparisons were performed using one-way analysis of variance followed by a Dunnett\'s test using SPSS 11.5.1 for Windows, 2002 (SPSS Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Body weight gain, liver weight, food intake and water intake

The body weight gains, liver weight, food intake and water intake during the experimental period are shown in [Table I](#tI-etm-0-0-4113){ref-type="table"}. The diabetic control mice showed a significant reduction in body weight in comparison with non-diabetic mice. However, the body weights of mice treated with persicarin were notably higher than those diabetic control mice. In addition, the administration of persicarin did not affect food and water intake, but the liver weight was significantly increased by \~1.19- and 1.2-fold in the low and high dose groups, respectively.

### Serum and hepatic functional parameters

[Table II](#tII-etm-0-0-4113){ref-type="table"} shows that the serum glucose level was significantly increased in diabetic control mice; the increase was \~4.9-fold in comparison with that in non-diabetic mice. Persicarin treatment led to a notable reduction of glucose level in a dose-dependent manner. Hepatic functional parameters, namely ALT and AST levels in the serum, of vehicle- and persicarin-treated diabetic mice were investigated. The activities of ALT and AST in the diabetic mice were significantly higher than those of normal mice, while their activities in the persicarin treatment groups were markedly reduced in a dose-dependent manner.

### Hepatic glucose

As [Table II](#tII-etm-0-0-4113){ref-type="table"} demonstrates, persicarin exhibited an effect on hepatic glucose. Persicarin administration markedly reduced hepatic glucose levels at a dose of 5 mg/kg.

### Biomarkers associated with oxidative stress in hepatic tissue

As shown in [Fig. 1](#f1-etm-0-0-4113){ref-type="fig"}, the biomarkers of oxidative stress, namely ROS, ONOO^−^ and TBARS in diabetic control mice were notably elevated compared with those in normal mice. However, the elevated levels were diminished by oral treatment with persicarin.

### Expression of NADPH oxidase subunits Nox-4 and p47^phox^ in hepatic tissue

The results of western blot analysis of hepatic Nox-4 and p47^phox^ protein in the hepatic tissues of the four groups are shown in [Fig. 2](#f2-etm-0-0-4113){ref-type="fig"}. Persicarin administration showed a tendency to decrease the Nox-4 level (although the reduction was not statistically significant), whereas the p47^phox^ protein expression level was significantly decreased.

### Inflammation-related protein expression in hepatic tissue

As is shown in [Figs. 3](#f3-etm-0-0-4113){ref-type="fig"} and [4](#f4-etm-0-0-4113){ref-type="fig"}, the levels of expression of various inflammation-related proteins, specifically, NF-κBp65, AP-1, iNOS, COX-2 and TGF-β were significantly increased in the livers of diabetic control mice compared with those in non-diabetic mice. NF-κBp65 and AP-1 protein levels were reduced significantly to become comparable with those of normal mice following treatment with persicarin. In addition, TGF-β and COX-2 protein expression levels were notably decreased by the administration of persicarin at a dose of 5 mg/kg. Furthermore, iNOS protein expression was significantly decreased in a dose-dependent manner by treatment with persicarin.

### Hepatic histological examination

Histological evaluation of the hepatocellular damage was conducted ([Fig. 5](#f5-etm-0-0-4113){ref-type="fig"}). The level of hepatocellular damage was higher in the vehicle-treated diabetic mice compared with normal mice. However, the administration of persicarin was observed to attenuate the hepatocellular damage in STZ-treated diabetic mice.

Discussion
==========

*O. javanica* has been used for many years for the treatment of inflammatory conditions, including hepatic damage ([@b24-etm-0-0-4113]). Previous studies have shown that it possesses anti-hepatitis B virus ([@b9-etm-0-0-4113]), antithrombotic ([@b10-etm-0-0-4113]) and anticancer activities ([@b15-etm-0-0-4113],[@b16-etm-0-0-4113]). Moreover, persicarin, a major flavonoid component isolated from *O. javanica* has been reported to have a hypoglycemic effect in a type 1 diabetes model ([@b12-etm-0-0-4113]), and to inhibit oxidative stress and inflammation in human endothelial cells and sepsis-induced mice ([@b17-etm-0-0-4113]). In addition, persicarin has been reported to exhibit hepatoprotective effects through the inhibition of lipid peroxidation; however, its underlying beneficial effects on diabetes-induced liver damage are unclear ([@b8-etm-0-0-4113]). In the present study, the protective activities of persicarin against diabetes-induced liver damage were evaluated.

Diabetes is characterized by polyuria, polydipsia and polyphagia symptoms ([@b25-etm-0-0-4113]). STZ also leads to abnormal metabolism, including increases in food intake and water intake and decreases in body weight gain and liver weight ([@b26-etm-0-0-4113],[@b27-etm-0-0-4113]). In the present study, the administration of persicarin for 10 days led to no change in food or water intake, but body weight gain and liver weight were significantly increased by both doses ([Table I](#tI-etm-0-0-4113){ref-type="table"}). These results indicate that oral treatment with persicarin ameliorates some of the common symptoms of diabetes. Diabetic mice exhibited serum and hepatic glucose levels that were significantly increased compared with those in normal mice. The serum and hepatic glucose levels of the persicarin-treated diabetic mice were lower than those of the vehicle-treated diabetic mice ([Table II](#tII-etm-0-0-4113){ref-type="table"}).

The levels of glucose transporter 2 protein (GLUT2) are upregulated in a dose-dependent manner according to glucose concentration ([@b28-etm-0-0-4113]). In addition, liver GLUT2 protein levels are increased in diabetic rats and downregulated by insulin ([@b29-etm-0-0-4113]). On this basis, it is suggested that the reduction of the glucose content in the liver tissue involved an improvement of insulin resistance through GLUT2 activity.

Hyperglycemia is a primary cause of increased generation of ROS, leading to increased oxidative stress under conditions where the antioxidant defense is damaged. Hyperglycemia is a continuous cause of oxidative stress in diabetes ([@b30-etm-0-0-4113]--[@b32-etm-0-0-4113]). Oxidative stress plays a important role in the progression of liver damage ([@b1-etm-0-0-4113]). In addition, hepatic injury has been found to be associated with an increase in production of ROS ([@b1-etm-0-0-4113],[@b3-etm-0-0-4113]). Mitochondria are one of the major sources of ROS, and they increase the production of ROS from the mitochondrial respiratory chain when they are functionally disordered ([@b33-etm-0-0-4113]). In hyperglycemia, NADPH oxidase is a main source of ROS production and the actions of mitochondrial respiratory chain complex enzymes are damaged as a result of continuous hyperglycemic conditions ([@b6-etm-0-0-4113],[@b34-etm-0-0-4113]). It is well recognized that in diabetic animal models, STZ results in the overexpression of ROS and generates nitric oxide (NO). NO combines with superoxide to form ONOO^−^, which causes lipid peroxidation, DNA damage and cell death. Therefore, it has a direct toxic effect on the liver leading to hepatic damage ([@b35-etm-0-0-4113]--[@b37-etm-0-0-4113]). In the present study, the elevated levels of NADPH oxidase subunits Nox-4 and p47^phox^ protein in the hepatic tissues of diabetic mice were notably reduced by the administration of persicarin. Moreover, the hepatic functional parameters ALT and AST of diabetic mice were markedly higher than those of normal mice; however, ALT and AST levels in the diabetic mice were significantly lowered by persicarin ([Table II](#tII-etm-0-0-4113){ref-type="table"}). These results suggest that persicarin improved hepatic functional parameters and exhibited hepatoprotective effects through downregulated oxidative stress via the modulation of Nox-4 and p47^phox^ protein expression.

Oxidative stress mediated by hyperglycemia leads to the overexpression of the redox responsive transcription factor NF-κB and AP-1, which modulates the increased gene expression required for the inflammatory response ([@b38-etm-0-0-4113]). Following an inflammatory response, the activation of NF-κB induces downstream inflammatory mediators such as TGF-β1, iNOS and COX-2 that have been reported to induce toxic effects in the liver ([@b39-etm-0-0-4113]). COX-2 is a key enzyme in prostaglandin biosynthesis from arachidonic acid and is associated with inflammatory processes ([@b40-etm-0-0-4113]). iNOS is another enzyme involved in inflammation and it catalyzes the formation of NO. NO reacts with superoxide to produce ONOO^−^, which is a highly ROS and leads to increased destructive and nitrosative stress ([@b41-etm-0-0-4113]). The overexpression of AP-1 increases TGF-β transcription, and AP-1 elements are found in the TGF-β promoter ([@b42-etm-0-0-4113]). In the present study, the livers of vehicle-treated diabetic mice showed significantly increased NF-κB and AP-1 levels in comparison with those of normal mice. However, the increased liver levels of NF-κB and AP-1 were notably reduced by persicarin. In addition, TGF-β, COX-2 and iNOS expression levels in the livers of diabetic mice were markedly increased compared with those of normal mice. Administration of persicarin decreased the TGF-β and COX-2 expression levels; the reduction was significant at a dose of 5 mg/kg. In addition, the iNOS expression level was significantly decreased by persicarin in a dose-dependent manner from a dose of 2.5 mg/kg through the NF-κB pathway. In the present study, the elevated protein expression of transcription factors (NF-κB and AP-1), pro-inflammatory enzymes (COX-2 and iNOS) and pro-inflammatory cytokine (TGF-β1) in the livers of diabetic mice were downregulated significantly by the administration of persicarin, suggesting that persicarin attenuates the inflammatory response by inhibiting the NF-κB and AP-1 pathway. Results also indicate that persicarin suppressed the symptoms of type 1 diabetes in STZ-induced mice. Persicarin ameliorated abnormal hepatic metabolism by decreasing hyperglycemia and oxidative stress (declining glucose and ROS production). Also, persicarin attenuated the inflammation associated with AP-1, NF-κB, COX-2, TGF-β1, and iNOS in the liver.

In conclusion, the results from this study suggest that persicarin protects against type 1 diabetes by attenuating oxidative stress and the inflammatory response under hyperglycemic conditions, as shown in [Fig. 6](#f6-etm-0-0-4113){ref-type="fig"}. Thus, it is suggested that persicarin may be a potential therapeutic agent for the treatment of diabetic complications including hepatic damage and diabetic symptoms.

![Levels of (A) ROS, (B) ONOO- and (C) TBARS in hepatic tissue. N, non-diabetic mice; veh, vehicle-treated diabetic mice; low, persicarin 2.5 mg/kg body weight-treated diabetic mice; high, persicarin 5 mg/kg body weight-treated diabetic mice. Data are the means ± standard error of the mean (n=6). \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001 vs. vehicle-treated diabetic mice. ROS, reactive oxygen species; ONOO-, peroxynitrite; TBARS, thiobarbituric acid-reactive substance.](etm-13-04-1194-g00){#f1-etm-0-0-4113}

![Expression of (A) Nox-4 and (B) p47phox protein in hepatic tissue. N, non-diabetic mice; veh, vehicle-treated diabetic mice; low, persicarin 2.5 mg/kg body weight-treated diabetic mice; high, persicarin 5 mg/kg body weight-treated diabetic mice. Data are the means ± standard error of the mean (n=6). \*P\<0.001 vs. vehicle-treated diabetic mice.](etm-13-04-1194-g01){#f2-etm-0-0-4113}

![Expression of (A) NF-κBp65 and (B) AP-1 protein expressions in hepatic tissue. N, non-diabetic mice; veh, vehicle-treated diabetic mice; low, persicarin 2.5 mg/kg body weight-treated diabetic mice; high, persicarin 5 mg/kg body weight-treated diabetic mice; NF-κBp65, nuclear factor-κ B; AP-1, activator protein-1. Data are the means ± standard error of the mean (n=6). \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001 vs. vehicle-treated diabetic mice.](etm-13-04-1194-g02){#f3-etm-0-0-4113}

![Expression of (A) COX-2, (B) iNOS and (C) TGF-β protein in hepatic tissue. N, non-diabetic mice; veh, vehicle-treated diabetic mice; low, persicarin 2.5 mg/kg body weight-treated diabetic mice; high, persicarin 5 mg/kg body weight-treated diabetic mice; COX-2, cyclooxygenase-2; iNOS, inducible nitric oxide synthase; TGF-β, transforming growth factor-β. Data are the means ± standard error of the mean (n=6). \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001 vs. vehicle-treated diabetic mice. .](etm-13-04-1194-g03){#f4-etm-0-0-4113}

![Hematoxylin and eosin staining of hepatic tissue in diabetic mice treated with persicarin for 10 days. (A) Non-diabetic mice, (B) vehicle-treated diabetic mice, (C) persicarin 2.5 mg/kg body weight-treated diabetic mice and (D) persicarin 5 mg/kg body weight-treated diabetic mice. Magnifcation, ×200.](etm-13-04-1194-g04){#f5-etm-0-0-4113}

![Predicted mechanism of persicarin against oxidative stress and inflammation in hepatic tissues. GLUT2, glucose transporter 2; ROS, reactive oxygen species; NO, nitric oxide; ONOO^−^, peroxynitrite; iNOS, inducible NO synthase; COX-2, cyclooxygenase-2; TGF-β, transforming growth factor-β; NF-κB, nuclear factor-κB; AP-1, activator protein-1.](etm-13-04-1194-g05){#f6-etm-0-0-4113}

###### 

Body weight, liver weight, food intake, and water intake.

                      Body weight                                                                                                                                                                                                                                  
  ------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------- --------- -----------
  Non-diabetic mice   38.9±0.6^[a](#tfn2-etm-0-0-4113){ref-type="table-fn"}^   42.0±0.6^[a](#tfn2-etm-0-0-4113){ref-type="table-fn"}^   3.6±0.2^[a](#tfn2-etm-0-0-4113){ref-type="table-fn"}^    7.9±0.3^[a](#tfn2-etm-0-0-4113){ref-type="table-fn"}^   5.1±2.6     6.1±3.0
  Diabetic mice                                                                                                                                                                                                                                                    
    Veh               33.9±0.8                                                 33.2±0.8                                                 −1.3±0.2                                                 6.1±0.1                                                 8.4±0.5   28.7±4.9
    Low               33.8±1.1                                                 33.9±1.5                                                 −0.4±0.3^[b](#tfn3-etm-0-0-4113){ref-type="table-fn"}^   7.3±0.3^[b](#tfn3-etm-0-0-4113){ref-type="table-fn"}^   7.8±0.2   35.2±3.4
    High              33.8±1.1                                                 33.3±1.2                                                 0±0.2^[a](#tfn2-etm-0-0-4113){ref-type="table-fn"}^      7.3±0.1^[a](#tfn2-etm-0-0-4113){ref-type="table-fn"}^   8.4±0.4   38.6±4.0

Data are presented as the mean ± standard error of the mean (n=6).

P\<0.001

P\<0.01 vs. vehicle-treated diabetic mice. Veh, vehicle-treated diabetic mice; low, persicarin 2.5 mg/kg body weight-treated diabetic mice; high, persicarin 5 mg/kg body weight-treated diabetic mice.

###### 

Biochemical analyses.

                                                                                                Diabetic mic                                                               
  --------------------------------- ----------------------------------------------------------- -------------- ----------------------------------------------------------- ------------------------------------------------------------
  Serum glucose (mg/dl)             122.15±5.54^[a](#tfn5-etm-0-0-4113){ref-type="table-fn"}^   597.12±7.39    533.96±9.94^[a](#tfn5-etm-0-0-4113){ref-type="table-fn"}^   513.11±19.86^[b](#tfn6-etm-0-0-4113){ref-type="table-fn"}^
  Hepatic glucose (mg/mg protein)   31.53±1.50^[c](#tfn7-etm-0-0-4113){ref-type="table-fn"}^    36.73±0.46     34.47±1.81                                                  33.56±0.35^[a](#tfn5-etm-0-0-4113){ref-type="table-fn"}^
  Serum ALT (IU/l)                  15.43±0.73^[a](#tfn5-etm-0-0-4113){ref-type="table-fn"}^    31.27±0.30     27.32±1.69                                                  25.64±0.51^[a](#tfn5-etm-0-0-4113){ref-type="table-fn"}^
  Serum AST (IU/l)                  51.98±3.49^[a](#tfn5-etm-0-0-4113){ref-type="table-fn"}^    120.08±4.27    93.32±1.01^[a](#tfn5-etm-0-0-4113){ref-type="table-fn"}^    86.03±3.09^[a](#tfn5-etm-0-0-4113){ref-type="table-fn"}^

Data are presented as the mean ± standard error of the mean.

P\<0.001

P\<0.01

P\<0.05 vs. vehicle-treated diabetic mice. Veh, vehicle-treated diabetic mice; low, persicarin 2.5 mg/kg body weight-treated diabetic mice; high, persicarin 5 mg/kg body weight-treated diabetic mice; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
